NCT01368783View on ClinicalTrials.gov

Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers

PHASE1UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2011

Conditions
Atazanavir
Interventions
DRUG

atazanavir

400 mg/day for 2 days

DRUG

Atazanavir(ATZ) and Tenofovir(TDF)

ATZ 400 mg with TDF/day for 2 days

DRUG

Atazanavir(ATZ) + Ritonavir

ATZ 300 mg + Ritonavir 100 mg/day for 2 days

DRUG

atazanavir(ATZ) + tenofovir(TDF) + ritonavir

ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days

Trial Locations (1)

138-736

Asan Medical Center, Songpa-gu

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Asan Medical Center

OTHER